In addition, other histotype-specific management strategies are now being adopted or investigated in ovarian cancer, including MEK inhibition for low-grade serous ovarian carcinoma and immunotherapy for clear cell ovarian carcinoma (2). The gene discussed is MAP2K7; the disease is ovarian cancer.